Nektar Therapeutics entered into an at-the-market equity offering agreement for up to $150 million in common stock and announced a transition of its interim CFO from Sandra Gardiner to Linda Rubinstein effective May 15, 2026.
Key takeaways
Entered Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for up to $150M ATM offering of common stock.
Shares offered via Form S-3 registration filed November 12, 2025, at market or negotiated prices on Nasdaq.
Sales agents receive 3.0% commission on gross sales price plus expense reimbursement.
Sandra Gardiner retiring as interim CFO effective May 15, 2026, after serving since April 2023.
Linda Rubinstein appointed interim CFO effective May 15, 2026, with $650/hour consulting rate via FLG Partners.